H-16, Hymenochirin-1B [D9K; E6,N10 S5]
General Information
DRACP ID DRACP02894
Peptide Name H-16, Hymenochirin-1B [D9K; E6,N10 S5]
Sequence IKLSPⓍTKKⓍLKKVLKGAIKGAIAVAKMV
Sequence Length 29
UniProt ID W8PRC4
PubChem CID Not available
Origin Synthetic (Derived from Hymenochirin-1B)
Type Synthetic peptide
Classification
Active ACP Stapled Peptides
Activity Information
Cell Line | Disease | Cancer Classified | Activity | Assay | Testing Time | Literature |
---|---|---|---|---|---|---|
A549 | Lung adenocarcinoma | Carcinoma | IC50=1.85±0.31 μM | MTT assay | 96 h | 1 |
HCT 116 | Colon carcinoma | Carcinoma | IC50=2.65±0.35 μM | MTT assay | 96 h | 1 |
HepG2 | Hepatoblastoma | Blastoma | IC50=3.14±0.46 μM | MTT assay | 96 h | 1 |
Hemolytic Activity Not available
Normal (non-cancerous) Cytotoxicity Not available
Target Not available
Affinity Not available
Mechanism Not available
Nature Anticancer
Structure Information
Helicity Not available
Linear/Cyclic Linear
Disulfide/Other Bond Stapled: Ⓧ(6) and Ⓧ (10) are cross-linked by hydrocarbon stapling
N-terminal Modification Free
C-terminal Modification Free
Other Modification Ⓧ=(S)-N-Fmoc-2-(4′-pentenyl)alanine
Chiral L
Physicochemical Information
Formula C132H241N35O28S
Absent amino acids CDEFHNQRWY
Common amino acids K
Mass 351828
Pl 11.65
Basic residues 8
Acidic residues 0
Hydrophobic residues 13
Net charge 8
Boman Index 274
Hydrophobicity 39.66
Aliphatic Index 124.48
Half Life
/
Extinction Coefficient cystines 0
Absorbance 280nm 0
Polar residues 4
Amino acid distribution
Literature Information
Literature 1
Pubmed ID 30789695
Title Improving Selectivity, Proteolytic Stability, and Antitumor Activity of Hymenochirin-1B: A Novel Glycosylated Staple Strategy
Doi 10.1021/acschembio.9b00046
Year 2019
Patent
Patent ID Not available
Patent Title Not available
Other Iinformation Not available
Other Published ID Not available
External Code
DBAASP ID DBAASPS_18016